Related Experiment Video
Updated: Jun 4, 2026
12:55
Scalable High Throughput Selection From Phage-displayed Synthetic Antibody Libraries
Published on: January 17, 2015
Developing Anti-HER2/neu Single-Chain Fv Fragments from Phage Display Libraries
Methods in Molecular Medicine
|February 23, 2011
Summary
Monoclonal antibodies (MAbs) show promise for B-cell lymphomas but struggle with solid tumors like ovarian cancer due to poor diffusion. Smaller antibody fragments (Fab) may offer improved tumor penetration for better cancer therapy.
Area of Science:
- Oncology
- Immunology
- Biotechnology
Background:
- Conventional cancer therapies lack sufficient toxicity differential between normal and cancerous tissues.
- Monoclonal antibodies (MAbs) were developed to target tumor-associated antigens, aiming for greater specificity.
- MAbs have shown success in B-cell lymphomas but not in solid tumors like ovarian carcinoma.
Purpose of the Study:
- To investigate the limitations of MAb delivery in solid tumors.
- To explore alternative antibody formats for improved tumor penetration.
Main Methods:
- Review of MAb efficacy in different cancer types.
- Analysis of diffusion characteristics of large IgG molecules versus smaller antibody fragments (Fab) in tumor interstitial environments.
Main Results:
- MAbs have demonstrated significant efficacy in treating B-cell lymphomas.
- Solid tumors, including ovarian carcinoma, present challenges due to disordered vasculature and high interstitial pressure, limiting MAb diffusion.
- Larger IgG molecules (150 kDa) diffuse slowly (1 mm in 2-3 days), while smaller Fab fragments (50 kDa) show faster interstitial movement (1-2 mm per day).
Conclusions:
- The physical properties of solid tumors impede the effective delivery of conventional MAbs.
- Smaller antibody fragments, such as Fab, exhibit superior diffusion characteristics within the tumor interstitium.
- Further research into antibody fragments may enhance targeted cancer therapy for solid malignancies.
